SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Cambridge Antibody Technology Group
An SI Board Since December 1999
Posts SubjectMarks Bans
625 23 0
Emcee:  Jongmans Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
575CAMBRIDGE, England, May 20 /PRNewswire-FirstCall/ -- Cambridge Antibody Technolonigel bates-5/20/2005
574New Phase III Data Shows Nearly Four Out Of Five Crohn's Patients Responded nigel bates-5/16/2005
573Cambridge Antibody Technology Announces Interim Results for the Six Months Endednigel bates-5/16/2005
572Humira sales for the quarter - <pre> Quarter Ended 3/31/05 (dollars inigel bates-4/12/2005
571Just guessing, but if it follows other CAT deals I'd say low to mid single dkeokalani'nui-4/7/2005
570Nigel, or anyone, any idea as to the royalty rates that would be due CAT? - AshlA.J. Mullen-4/6/2005
569LymphoStat-B PII results - Message 21202169nigel bates-4/6/2005
568Cambridge Antibody Technology Announces Preliminary Results of Second Pivotal TrA.J. Mullen-3/22/2005
567Cambridge Antibody Technology Legal Action With Abbott: Abbott Granted Permissionigel bates-3/21/2005
566Newly Published Study Evaluates Abbott's HUMIRA(R) in Crohn's Disease Monigel bates-1/31/2005
565Lovely. <i>Part of these costs will be assessed, as sought by CAT, on a hkeokalani'nui-1/28/2005
564Cambridge Antibody Technology Legal Action With Abbott: Ruling on Procedural Matscaram(o)uche-1/28/2005
563Abbott Lab To Appeal Vs Cambridge Antibody Royalty Ruling Friday January 28scaram(o)uche-1/28/2005
562Friday January 28, 11:53 AM EST LONDON -(Dow Jones)- UK biotechnology company scaram(o)uche-1/28/2005
561<<if you have a great feeling for IL-12 >> Synta (SNTA) S-1 Subjectmichael_f_murphy-1/19/2005
560Last quarter Humira sales <pre> Q2) How did HUMIRA perform in the quartnigel bates-1/18/2005
559I agree that the market hasn't fully valued this company. My personal rough goyster-12/21/2004
558>>Back to catg, I don't get the Abbott case. Hard to see why abt thougkeokalani'nui-12/21/2004
557Decided to post here instead of reply on nbix. PC has done a great job, esp imrkrw-12/21/2004
556Not that I'm aware of. Could it be a US withholding tax ?nigel bates-12/21/2004
555Thanks for the clarification. I didn't catch the tax inclusion on my first rrkrw-12/21/2004
554It's a report from Lehman, and here's what it claims: 2% royalty producBiomaven-12/21/2004
553<<<My guess is rkrw's report said, or meant, the incremental increarkrw-12/21/2004
552a little bit more on gross royalty from wsj today: <snip> Abbott had beefred hayes-12/21/2004
551My guess is rkrw's report said, or meant, the <i>incremental increase keokalani'nui-12/21/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News